Dennis W. Dickson

3 weeks ago | nature.com | Christopher Schwarz |Matthew L. Senjem |Prashanthi Vemuri |Leah Forsberg |David Jones |Hugo Botha | +7 more

AbstractDementia with Lewy bodies (DLB) frequently coexists with Alzheimer’s disease pathology, yet the pattern of cortical microstructural injury and its relationship with amyloid, tau, and cerebrovascular pathologies remains unclear.

1 month ago | nature.com | Cyril Pottier |Fahri Küçükali |Matt Baker |Gregory Jenkins |Cristina T. Vicente |Wouter De Coster | +55 more

AbstractFrontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci identified.

Jun 20, 2024 | nature.com | Özkan İş |Xue Wang |Joseph S. Reddy |Yuhao Min |Elanur Yilmaz |Prabesh Bhattarai | +19 more

AbstractTo uncover molecular changes underlying blood-brain-barrier dysfunction in Alzheimer’s disease, we performed single nucleus RNA sequencing in 24 Alzheimer’s disease and control brains and focused on vascular and astrocyte clusters as main cell types of blood-brain-barrier gliovascular-unit. The majority of the vascular transcriptional changes were in pericytes.

Apr 2, 2024 | nature.com | Christopher Schwarz |Matthew L. Senjem |Dennis W. Dickson |Bradley F. Boeve

AbstractDementia with Lewy bodies (DLB) is a neurodegenerative condition often co-occurring with Alzheimer’s disease (AD) pathology. Characterizing white matter tissue microstructure using Neurite Orientation Dispersion and Density Imaging (NODDI) may help elucidate the biological underpinnings of white matter injury in individuals with DLB.

Nov 2, 2023 | nature.com | Yuhao Min |Xue Wang |Joseph S. Reddy |Zachary Quicksall |Thuy Nguyen |Thụy Tường Nguyễn | +3 more

AbstractProgressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder characterized by cell-type-specific tau lesions in neurons and glia. Prior work uncovered transcriptome changes in human PSP brains, although their cell-specificity is unknown. Further, systematic data integration and experimental validation platforms to prioritize brain transcriptional perturbations as therapeutic targets in PSP are currently lacking.